Annual Report

The report describes a strong 2009 for ALK, with group revenue of DKK 1,935 million and continued growth in its allergy-vaccine business. Its CSR disclosures report ISO 14001 environmental certification and OHSAS 18001 health and safety certification across the organization. The company also set a target to reduce CO2 emissions by 15% or more by 2014 against 2008, while total energy consumption rose 18% year-on-year. Year-end employment was 1,554.